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Background: Long non-coding RNAs (lncRNAs) are emerging as molecules that significantly impact many cellular
processes and have been associated with almost every human cancer. Compared to protein-coding genes, lncRNA
genes are often associated with transposable elements, particularly with endogenous retroviral elements (ERVs).
ERVs can have potentially deleterious effects on genome structure and function, so these elements are typically
silenced in normal somatic tissues, albeit with varying efficiency. The aberrant regulation of ERVs associated with
lncRNAs (ERV-lncRNAs), coupled with the diverse range of lncRNA functions, creates significant potential for
ERV-lncRNAs to impact cancer biology.
Methods: We used RNA-seq analysis to identify and profile the expression of a novel lncRNA in six large
cohorts, including over 7,500 samples from The Cancer Genome Atlas (TCGA).
Results: We identified the tumor-specific expression of a novel lncRNA that we have named Endogenous
retroViral-associated ADenocarcinoma RNA or ‘EVADR’ , by analyzing RNA-seq data derived from colorectal
tumors and matched normal control tissues. Subsequent analysis of TCGA RNA-seq data revealed the striking
association of EVADR with adenocarcinomas, which are tumors of glandular origin. Moderate to high levels of
EVADR were detected in 25 to 53% of colon, rectal, lung, pancreas and stomach adenocarcinomas (mean = 30
to 144 FPKM), and EVADR expression correlated with decreased patient survival (Cox regression; hazard ratio = 1.47,
95% confidence interval = 1.06 to 2.04, P = 0.02). In tumor sites of non-glandular origin, EVADR expression was
detectable at only very low levels and in less than 10% of patients. For EVADR, a MER48 ERV element provides
an active promoter to drive its transcription. Genome-wide, MER48 insertions are associated with nine lncRNAs,
but none of the MER48-associated lncRNAs other than EVADR were consistently expressed in adenocarcinomas,
demonstrating the specific activation of EVADR. The sequence and structure of the EVADR locus is highly conserved
among Old World monkeys and apes but not New World monkeys or prosimians, where the MER48 insertion is absent.
Conservation of the EVADR locus suggests a functional role for this novel lncRNA in humans and our closest
primate relatives.
Conclusions: Our results describe the specific activation of a highly conserved ERV-lncRNA in numerous
cancers of glandular origin, a finding with diagnostic, prognostic and therapeutic implications.* Correspondence: egibb@bcgsc.ca
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The mammalian transcriptome is pervasively transcribed
[1-4]. Comprehensive transcriptome sequencing surveys
have revealed many classes of widely expressed non-coding
RNAs, including long non-coding RNAs (lncRNAs) [5].
These novel genes encode mRNA-like transcripts that are
by definition at least 200 nucleotides in length and have
no apparent protein coding capacity, but are otherwise
subject to normal mRNA processing, including 5′ cap-
ping, splicing and polyadenylation [6]. Many lncRNAs
demonstrate exquisite cellular-, tissue- or developmental
stage-specific expression patterns [7-9]. lncRNAs have a
range of demonstrated functions, including chromatin re-
modeling [10], alternative splicing [11] and mRNA deg-
radation [12], and their dysregulation has been linked to
many disorders, including cancer [13-15].
Compared with protein-coding genes, lncRNA genes
tend to associate with transposable elements, particularly
with endogenous retroviruses (ERVs) [16-18]. The ma-
jority of ERVs are genomic relics of exogenous retrovirus
insertions which, although typically degenerated, may re-
tain active promoter and polyadenylation signals encoded
within their flanking long terminal repeats (LTRs) [19,20].
Through these active regulatory elements, both ERVs
and other retrotransposons contribute significantly to the
regulation of gene expression [21,22]. However, unregu-
lated ERV LTRs can promote aberrant transcription and
are therefore typically silenced in adult tissues by epigen-
etic mechanisms including, but not limited to, DNA
methylation [23,24]. In cancer, silenced ERVs may be
released from normal cellular regulation, resulting in a
general increase in ERV-mediated transcription [25-27].
Given the frequency and scattered genomic distribution of
ERVs and the influence of their LTRs on the expression of
neighboring genes, ERVs have high potential to promote
oncogene expression or to alter host gene expression net-
works to favor tumor development [25]. Similarly, changes
in physiological or cellular conditions that promote class-
specific ERV LTR expression could promote the activa-
tion of lncRNAs associated with that class, as has been
observed for HERV-H LTRs in embryonic stem cells
[18,28]. Considering the range of biological functions de-
scribed for lncRNAs and their role in gene regulation,
ERV-mediated lncRNA activation has considerable poten-
tial to impact cellular biology.
To further characterize the relationship between aberrant
lncRNA expression and cancer, we evaluated RNA-seq data
from colorectal adenocarcinoma and matched normal con-
trol tissues from 65 subjects for lncRNA expression. We
identified a 394-nucleotide MER48 LTR ERV-associated
lncRNA ‘EVADR’ as being robustly expressed in tumor
samples, with virtually no expression in corresponding
normal tissues. We then profiled the EVADR lncRNA
across 25 different cancer types, determined the promoteractivity of the MER48 LTR in vitro, mapped the genome-
wide MER48 LTR expression, and surveyed the conserva-
tion of the EVADR gene locus across 13 primates. Here
we report the identification and initial characterization
of EVADR.
Methods
Cancer, normal tissue and cell line transcriptome datasets
All sequence files were obtained with permission and
stored in a secure file system. The sequence data used in
this study are listed in Table 1.
Ethics
The research described herein conformed to the Helsinki
Declaration. All clinical specimens were obtained previ-
ously [33] with informed consent by the BC Cancer
Agency Tumor Tissue Repository (BCCA-TTR), which
operates as a dedicated biobank with approval from the
University of British Columbia-British Columbia Cancer
Agency Research Ethics Board (BCCA REB; certificate
#H09-01268).
RNA-seq read mapping
Raw sequence reads were aligned to the human refer-
ence genome and transcriptome (hg19, Ensembl v.70)
using STAR v.2.3.0e [34] or TopHat v.2.0.6 [35]. STAR
was run with the following parameters: minimum/max-
imum intron size set to 30 and 500,000, respectively,
noncanonical, unannotated junctions were removed,
maximum tolerated mismatches was set to 10, and the
outSAMstrandField intronMotif option was enabled. For
TopHat reads aligned to human ribosomal RNA se-
quences (18S, 28S, 5S) were removed, and the remaining
reads were aligned to human gene annotations (hg19,
Ensembl v.70) using default command line options ex-
cept the minimum isoform fraction option was set to 0.
The Cuffdiff command included with Cufflinks v.2.0.2
[36] was used to calculate the fragments per kilobase of
exon per million fragments mapped (FPKM) with upper
quartile normalization, fragment bias correction, and
multiread correction enabled. All other options were set
to default.
Targeted read assembly (TASR)
Targeted read assembly was performed using TASR
v.1.5.1 with the following parameters enabled: -m 20 -o
2 -i 1 [37]. Briefly, the 397-nucleotide EVADR cDNA se-
quence (ENST00000418403) was used as the target for
TASR, which extracted overlapping k-mers (-k 15) from
this sequence as seeds. These were used to recruit EVADR
RNA-seq reads from The Cancer Genome Atlas (TCGA)
bam files, and the set of reads recruited from each sample
was independently assembled de novo. Sequence contigs
of 200 nucleotides and larger were aligned to the EVADR
Table 1 RNA-seq datasets used in this study
Server Dataset ID Description Download host
SRA SRP010181 Colorectal cancer tumor matched normal libraries (n = 130) [29]
CGhub Various Twenty-five different cancers and normal tissues (n = 7,677) from TCGA [30]
GEO GSE40419 Lung adenocarcinoma tumor matched normal libraries (n = 144) [31]
GEO GSE30611 Human Bodymap 2.0 representing 16 normal human tissues [31]
ENCODE Various Fastq files from 15 different cell lines, replicates downloaded where available [32]
SRA SRP008280 Triplicate control K562 cell RNA-seq [29]
GEO, Gene Expression Omnibus; SRA, Sequence Read Archive; TCGA The Cancer Genome Atlas.
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8 -F F -p blastn -m 7), keeping only assembled tran-
scripts with 90% or higher sequence identity [38]. The
number of sequence reads assembled was tallied in each
TCGA sample and RPK (reads per kilobase) and RPKMS
(reads per kilobase per million sequenced) values were
calculated [39].
RT-PCR
RNA and cDNA were generated as described [40]. In
this study, cDNA from tumor or normal tissues was
used as a template for PCR using primers oHL_0005
and oHL_0006 (Table 2). The reaction was performed
for 35 cycles with Taq DNA polymerase (NEB, Ontario,
Canada) in supplied buffer and amplicons were resolved
on a 1% agarose gel.
Cell culture
K562 and SW480 cells were cultured in Dulbecco's
modified Eagle's medium (DMEM) supplemented with
10% fetal bovine serum and penicillin (100 units/ml)-
streptomycin (100 μg/ml) (Life Technologies, Ontario,
Canada). Cells were maintained at 37°C in a 5% CO2
incubator.
Plasmids
The MER48 promoter deletion plasmid constructs were
generated by first amplifying the MER48 element spe-
cific to EVADR using primers oHL_0011 and oHL_0005.Table 2 Primer sequences
Oligo Purpose
oHL_0005 Forward RT-PCR primers for EVADR transcript
oHL_0006 Reverse RT-PCR primers for EVADR transcript
oHL_0011 Clone MER48 LTR upstream of EVADR. XhoI/Hin
oHL_0012 Clone MER48 LTR upstream of EVADR. XhoI/Hin
oHL_0015 Cloning small fragment of MER48 element
oHL_0013 Clone MER48 LTR upstream of EVADR. XhoI/Hin
oHL_0016 Same as oHL_0011 but reversed restriction site
oHL_0017 Same as oHL_0012 but reversed restriction site
oHL_0014 Same primer as oHL_0006 but for cloning 5′RAThe subsequent amplicon was gel purified, diluted 1:100
and used as a template for amplifying each truncated
version of the MER48 element: MER1F, oHL_0011 and
oHL_0013; MER2F, oHL_0012 and oHL_0013; MER3F,
oHL_0015 and oHL_0013; and MER_FLIP, oHL_0016
and oHL_0013. Amplicons were digested with XhoI and
HindlII, gel purified and ligated into the pGL4 vector
(Promega, Wisconsin, United States).
Reporter assays
K562 cells were suspended in Electroporation Buffer
(20 mM HEPES, 137 mM NaCl, 5 mM KCl, 0.7 mM
Na2HPO4, 6 mM dextrose, 50 mM trehalose, 1% DMSO)
with 30 μg plasmid and electroporated at 200 V, 975 μF
capacitance. SW480 cells were grown to 60% confluency
and then reverse transfected using Lipofectamine 2000
(Life Technologies, Ontario, Canada) according to the
manufacturer’s instructions. The cells were harvested
24 h after electroporation (for K562) or 48 h after trans-
fection (for SW480), and firefly and Renilla luciferase ac-
tivities were analyzed with the Dual-Luciferase® Reporter
Assay System, according to the manufacturer’s instructions
(Promega, Wisconsin, United States). All experiments were
repeated in triplicate.
RNA ligase-mediated rapid amplification of cDNA ends
5′ Rapid amplification of cDNA ends (RACE) was per-
formed with a RLM-RACE kit (Life Technologies, Ontario
Canada) according to the manufacturer’s instructionsSequence (5′-3′)
TGATGCCATTTTCAGCCTCAG
TGGCCGCTCAGATTCTCTATC
dIII GGCTCGAGTAAGGGAATGAATAACTCCG
dIII GGCTCGAGATATGTACCCTGTGAAGACC
GGCTCGAGGTGCTGATGCCATTTTCAGCC
dIII GGAACCTTACATGCTGTTTTAATGAGCG
. XhoI CCAAGGTTTAAGGGAATGAATAACTCCG
. HindIII GGCTCGAGACATGCTGTTTTAATGAGCG
CE products CCGGATCCTGGCCGCTCAGATTCTCTATC
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primer oHL_0014.
MER48 expression patterns from K562 cell line data
A list of 201 reliable MER48 coordinates was obtained
from Dfam [41]. This list was used to count reads align-
ing to MER48 elements from two replicate K562 tran-
scriptome .bam files obtained from ENCODE using
readcount v0.01 with all options set to default.
Statistical tests
All statistical tests were performed using R v.3.1.0.
Tumor and normal expression comparisons
For each of the colorectal and lung cancer datasets, we
compared the difference between mean tumour expres-
sion values and mean normal tissue expression values
using a two-sample paired t-test.
STAR/Cufflinks and TASR expression correlations
The Pearson correlation coefficient was used to quantify the
strength of the correlations between the STAR/Cufflinks-
and TASR-generated expression levels.
EVADR tumor site association
All patients for each cancer type were classified accord-
ing to whether EVADR was detectable (>0 RPKMS).
Next, we counted the total number of patients in the
two groups (adenocarcinoma and non-adenocarcinoma),
with and without detectable EVADR expression. Using
these counts, we performed a Chi-squared test to test
the significance of the observed association of EVADR
expression and adenocarcinoma.
Reporter assays
The dual luciferase promoter mapping data were subjected
to t-tests with unequal variance followed by Bonferroni
correction, comparing the mean relative luciferase units
(RLU) of the MER1F construct with the RLUs of each of
the MER2F, MER3F and MER_FLIP constructs, in each of
the K562 and SW480 cell lines.
Correlation of MER48-lncRNA expression
For each cancer type we performed an ANOVA test to test
the null hypothesis that the expression of all MER48-
lncRNAs were the same. A significant result from ANOVA
was obtained for each of the five cancer types, which
prompted a subsequent Tukey’s honest significant differ-
ence post hoc test to identify which MER48-lncRNAs were
differentially expressed in each cancer type.
Structural conservation
Using the program Molecular Evolutionary Genetics
Analysis (MEGA) v.6 [42], we inferred the evolutionaryhistory of the primates using the maximum parsimony
method and EVADR cDNA alignments. The resultant
tree (Figure S1 in Additional file 1) was used to count
the number of nucleotide changes in context of EVADR
evolution in primates. To test the differences in the
number of variable positions in base-paired sequences
(structured regions) compared with non-structured se-
quences, we used a Chi-squared test to compare the
count of sites in structured and non-structured sequence
classes lacking perfect sequence conservation across all
studied species. To test whether the observed nucleotide
substitutions in structured regions were more likely to
maintain base pairing than expected by chance, we used
a Chi-squared test to compare the observed distribution
with the distribution expected by random substitutions.
To create this null distribution, we tallied for GC, GU
and AU base pairs all possible random nucleotide substi-
tutions (eight per pair, including single nucleotide dele-
tions). Of the 24 possible combinations, four nucleotides
are expected to still base pair after random mutation.Sequence identity calculations
Genomic alignments were generated using ClustalW
and imported into Jalview2 [43] for manual curation.
The polished alignments were exported as a ClustalW
alignment file and uploaded to the SIAS [44] website to
determine the sequence identity of EVADR between pri-
mates. We included parameters to take gaps into account
and used the BLOSUM62 matrix; all other settings were
set to default. The tree was generated using the UCSC
genome tool phlyoGif [45,46].Coding potential analysis
To confirm that EVADR was non-coding, we used the
online coding potential calculator tool (CPC) to calcu-
late EVADR’s coding potential [47]. As a positive control,
we included the cancer-associated lncRNA UCA1. The
results of this analysis were both transcripts were con-
sidered to be non-coding, with a CPC score of -1.29 for
EVADR and -1.14 for UCA1, where values between -1
and 1 are marked as ‘weak non-coding’ or ‘weak coding’,
respectively. Non-coding RNAs score below -1 and pro-
tein coding genes score above 1.
Using the online tool ORF Finder [48], we identified
three putative open reading frames (ORFs) within EVADR,
including one ORF with a non-AUG start codon (Figure
S2 in Additional file 1). To determine whether these ORFs
were actively translated, we queried several K562 prote-
omic datasets from studies that specifically evaluated the
presence of small peptides and found no evidence for
translation of the EVADR ORFs [49-51]. These findings
further support the classification of EVADR as a lncRNA
with little to no apparent translation.
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The MER48-lncRNA heatmaps were clustered using cen-
troid linkage and Euclidean distance in custom Python
scripts.
Genome mining MER48-associated lncRNAs
Dfam was used to identify MER48 elements within 500 bp
or 50 bp of a predicted lncRNA transcriptional start site
using Ensembl v.70 annotations. We identified nine candi-
dates using 500 bp and eight using 50 bp; in both cases
EVADR was included. Manual examination of the ex-
cluded lncRNA ENSG00000265374 revealed the MER48
formed part of the exon of the lncRNA, but the transcrip-
tional start site was upstream of the repeat element. We
included this lncRNA in our analyses.
Results
Identification of a highly upregulated long non-coding
RNA in colorectal carcinoma
To identify lncRNAs associated with colorectal cancer,
we performed whole transcriptome sequence analysis
on 65 tumor and matched normal colorectal poly(A)-
selected RNA-seq libraries generated in a previously
described study [33]. From these data we identified
two Ensembl-curated yet uncharacterized lncRNAs,
ENSG00000222041 and ENSG00000237643, which were
strongly upregulated in colorectal tumors compared with
matched normal control tissues. We did not characterize
ENSG00000222041 further because its differential expres-
sion was less substantial than that of ENSG00000237643,
and because it had a complex alternative splicing pattern
that complicated further analysis. Further scrutiny of
ENSG00000237643 (which we named EVADR for En-
dogenous retroViral-associated ADenocarcinoma RNA)
revealed significantly increased expression of this lncRNA
in tumors (14.4 ± 24.5 FPKM (mean ± standard deviation
(SD))) compared with matched normal control tissues,
where it was typically not expressed (0.50 ± 1.52 FPKM
(mean ± SD)) (Figure 1a; P = 2.8e-05; t-test). Genomic ana-
lysis revealed a predicted 397-nucleotide lncRNA with
three exons and a single transcript isoform located on
chromosome 6, 91.8 kb downstream of Col9A1 and
13.5 kb upstream of FAM135A (Figure 1b). Despite high
expression of EVADR in tumor samples, we did not ob-
serve differential expression of genes flanking EVADR
(Figure 1b). We designed primers to amplify a 200 bp re-
gion of the mature EVADR transcript and validated the
expression of this lncRNA in the colorectal tumor and
normal tissues using RT-PCR (Figure 1c,d; Additional file 2).
To corroborate our observation that EVADR was not
expressed in non-malignant tissue, we measured EVADR
expression in 16 normal adult human tissues finding only
weak expression in lung and prostate tissues (Figure S3A
in Additional file 1). Expanding these analyses to 15 celllines, we found that EVADR was highly expressed (122
FPKM) in the chronic myeloid leukemia K562 cell line,
but its expression was extremely low (<1 FPKM) in the
others, including in the H1-HESC embryonic stem cell
line (Figure S3B in Additional file 1), where it was 0.04
FPKM. These data demonstrate that EVADR is selectively
expressed.
Pan-cancer analysis reveals high activation of EVADR in
human adenocarcinoma
The striking expression pattern observed for EVADR in
colorectal carcinoma prompted us to perform add-
itional analysis across a broad panel of human cancers.
We queried EVADR expression in all available tumor (n =
7,043) and normal (n = 634) RNA-seq libraries from
TCGA Research Network project. Because full transcrip-
tome assembly requires significant compute resources we
opted to analyze TCGA RNA-seq data specifically for
EVADR expression using the targeted de novo assembler
TASR [37], which is much faster in situations where
transcriptome-wide information is not required. To con-
vert TASR-derived assemblies to expression values, we tal-
lied assembled sequence reads and calculated the RPKMS.
To determine the concordance between Cufflinks-derived
FPKMs and TASR-derived RPKMS we compared EVADR
expression across 181 colon adenocarcinoma (COAD) sam-
ples and observed a Pearson correlation of r = 0.93. Next, we
used TASR to quantify EVADR expression in 7,677 tumor
and normal TCGA RNA-seq datasets (Figure 2a). Consist-
ent with our initial observation that EVADR was specific-
ally upregulated in colorectal tumors, we found that this
lncRNA was detected in TCGA colon and rectal tumor
datasets at high (mean 25.3 ± 22.7 RPKMS (mean ± SD))
expression levels (Figure 2a,b). Strikingly, we also found
high EVADR expression in numerous lung (LUAD), pan-
creatic (PAAD), and stomach (STAD) adenocarcinomas
(12.3 ± 13.8, 12.1 ± 17.2, and 3.7 ± 7.7 RPKMS, respect-
ively; Figure 2a,b; Figure S4 in Additional file 1). We found
that while 481 out of 1,223 adenocarcinomas expressed
EVADR at detectable levels, only 50 out of 5,289 non-
adenocarcinomas expressed EVADR. We performed a
Pearson’s Chi-squared test comparing these two groups
and found that EVADR was significantly (P < 2.2e-16) as-
sociated with adenocarcinomas, but not with the other
tumor types. Having confirmed high EVADR expression
in the colorectal tumors in two independent datasets, we
also validated the cancer association of EVADR in a non-
colorectal tumor and matched normal control tissue data-
set. We processed an independent lung adenocarcinoma
transcriptome dataset [52] using Cufflinks [36], and ob-
served high EVADR expression in the tumors (9.84 ± 24.7
FPKM (mean ± SD)) and weak or undetectable expression
in normal tissues (mean 0.44 ± 0.55 FPKM (mean ± SD))
(P = 0.002; t-test; Figure S5 in Additional file 1). These
Figure 1 A long non-coding RNA is highly activated in colorectal tumors. (a) Expression of EVADR in tumor and adjacent normal tissue
from 65 patients with colorectal carcinoma. For each subject (x-axis) tumor is shown in red and normal tissue in grey. The dashed line
indicates an arbitrary minimum expression threshold of 10 FPKM. A total of 21 patients demonstrated robust (>10 FPKM) levels of EVADR
expression. Normal colon tissue was generally not found to express EVADR or it was expressed at low levels (<10 FPKM). (b) Schematic
representation of the chromosomal location of the EVADR gene locus. Arrowheads indicate the orientation of transcription. Bar plots
indicate mean expression levels for respective genes across all 65 tumor (COL91A, 0.25 ± 1.11 FPKM; EVADR, 14.4 ± 24.5 FPKM; FAM135A,
7.2 ± 3 FPKM (mean ± SD)) and normal samples (COL91A, 0.19 ± 0.53 FPKM; EVADR, 0.50 ± 1.52 FPKM; FAM135A, 5 ± 2.6 FPKM (mean ± SD)).
*P < 0.00001; paired t-test. (c) Exon structure and primer locations for the lncRNA EVADR. (d) Representative gel image showing EVADR transcript levels
in colorectal tumor (T32) and matched normal (N32) tissue samples for patient 32, measured by RT-PCR. The letter L indicates the molecular ladder.
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lung adenocarcinoma observed in the TCGA samples.
Clinical features of EVADR track with poor prognosis in
adenocarcinomas
Having observed specific and high-level expression of
EVADR in the tumors of patients with lung, colon, rec-
tal, stomach and pancreatic adenocarcinoma, we soughtto identify any possible clinical relevance of the associ-
ation of EVADR with these tumor types. To explore this
possibility, we selected TCGA datasets for these five
adenocarcinoma tumor types because of their large patient
cohorts and the availability of corresponding clinical data.
Using a Cox proportional-hazard model that accounted for
known prognostic factors (age, gender, type of adenocar-
cinoma, and tumor stage) as well as EVADR expression
Figure 2 EVADR is robustly expressed in adenocarcinomas. (a) EVADR expression in 25 TCGA cancer types and corresponding normal tissues.
Light orange indicates the tumors analyzed and light grey indicates normal samples analyzed. The hashtag (#) indicates that 916 BRCA samples
were analyzed. Dark red indicates the number of adenocarcinoma samples in which EVADR expression was detected, while dark grey indicates
the number of normal samples in which EVADR was detected. (b) EVADR expression as log2(RPKMS + 1), determined for tumors using TASR.
Medians are indicated by red lines, upper and lower quartiles by the boxes, and outliers by blue crosses. COAD, colon adenocarcinoma; LUAD,
lung adenocarcinoma; STAD, stomach adenocarcinoma; READ, rectum adenocarcinoma; PAAD, pancreatic adenocarcinoma; BLCA, bladder
urothelial carcinoma; PRAD, prostate adenocarcinoma; LUSC, lung squamous cell carcinoma; HNSC, head and neck squamous cell
carcinoma; ACC, adrenocortical carcinoma; KIRP, kidney renal papillary cell carcinoma; BRCA, breast invasive carcinoma; LIHC, liver
hepatocellular carcinoma; KIRC, kidney renal clear cell carcinoma; UCEC, uterine corpus endometrial carcinoma; CESC, cervical squamous
cell carcinoma and endocervical adenocarcinoma; SKCM, skin cutaneous melanoma; LGG, brain lower grade glioma; KICH, kidney
chromophobe; OV, ovarian serous cystadenocarcinoma; GBM, glioblastoma multiforme; DLBC, lymphoid neoplasm diffuse large B-cell
lymphoma; SARC, sarcoma; THCA, thyroid carcinoma; UCS, uterine carcinosarcoma.
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[53]), we saw a significantly (P < 0.02) decreased overall sur-
vival for patients with high EVADR expression (Figure 3).
These data associate elevated EVADR expression with lower
overall survival for the five TCGA tumor types investigated.
An ERV LTR contributes a functional promoter to EVADR
Detailed sequence analysis of the EVADR genomic locus
revealed sequence identity with a MER48 LTR, which is
an endogenous retroviral element of the ERV1 family
(Figure 4a) [54]. The MER48 LTR contributes 127 nucleo-
tides to the primary sequence of the 5′ exon of EVADR,
and also encodes numerous transcription factor bindingsites and a putative TATA box, suggesting a possible role
for these regulatory sequences in the transcriptional acti-
vation of EVADR in adenocarcinoma. As K562 cells
strongly express EVADR, we selected these cells for 5′-
RACE [55] and mapped three distinct 5′ transcript ter-
mini to the EVADR MER48 LTR, each downstream of the
predicted TATA box (Figure 4b). These data refine the
length of the predominant EVADR transcript from the
predicted value of 397 nucleotides to the confirmed value
of 394 nucleotides. To experimentally test the capacity of
the MER48 LTR in driving downstream transcription, we
generated a series of truncated MER48 constructs and
measured promoter activity, in triplicate, using a dual
Figure 3 Overall survival decreases for adenocarcinoma
patients expressing EVADR. Kaplan-Meier curves were constructed
using a univariate Cox analysis, stratifying patients based on EVADR
levels in tumor, with patients expressing high (>5.6 FPKM) levels of
EVADR showing decreased survival when compared with those with
low (<5.6 FPKM) expression (hazard ratio = 1.47, 95% confidence
interval = 1.06 to 2.04, P = 0.02). Tick marks on the graph denote the
last time survival status was known for living patients.
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tive in both K562 and SW480 cells (MER1F; K562, 73.7 ± 5.1
RLU (mean ± SD); SW480 8.14 ± 0.40 RLU), each subse-
quent 5′ truncation dramatically reduced luciferase
activity (MER2F; K562, mean 1.45 ± 0.14 RLU; SW480,
1.26 ± 0.08 RLU), with negligible promoter activity ob-
served for MER48 sequence overlapping with the 5′ exon
of EVADR (MER3F; K562, 0.08 ± 0.01 RLU; SW480,
0.10 ± 0.01 RLU) (Figure 4d,e). Surprisingly, we observed
strong luciferase activity when the EVADR MER48 LTR
was in the opposite orientation (MER_FLIP; K562, 198 ±
15.4 RLU; SW480, 23.6 ± 2.4 RLU), indicating the MER48
LTR can function as a bidirectional promoter (Figure 4d,e;
MER_FLIP). Despite the high transcriptional activity ob-
served from the MER_FLIP plasmid constructs, we found
no evidence supporting bidirectional transcription in vivo
(Figure S6 in Additional file 1). These results demonstrate
that the MER48 LTR not only contributes to the 5′ exon
of EVADR, but also provides a promoter sequence capable
of driving the transcription of this lncRNA.
EVADR is selectively upregulated in adenocarcinomas
A MER48 LTR is found within 500 bp of the annotated
transcriptional start sites of nine Ensembl annotated
lncRNAs. To determine if EVADR expression is due to a
general activation of MER48 LTR elements in adenocar-
cinomas, we queried the expression of the other eightnon-EVADR MER48-associated lncRNAs in colon, rectal,
pancreas, stomach and lung tumors using Cufflinks [36].
These tumor types were selected because they included
large numbers of patients that expressed EVADR at high
levels. EVADR clustered independently of other MER48-
lncRNAs and of tumor type (Figure 5a). Next, we deter-
mined the distribution of lncRNA expression for all
MER48-lncRNAs in each of the five different types of
adenocarcinoma, and for each type we observed sig-
nificantly elevated expression of EVADR relative to all
other MER48-lncRNAs (P < 2e-16 for each cancer type;
ANOVA with Tukey’s honest significant difference post
hoc test; Figure 5b). Additionally, in lung adenocarcinoma,
ENSG00000231106 is also expressed differently from all
other MER48-lncRNAs (including EVADR). Finally, to de-
termine whether MER48 LTRs were universally active, we
queried the expression of 201 Dfam-curated MER48 LTRs
in K562 cells and found that the MER48 LTR associated
with EVADR is specifically and highly activated, while the
remaining MER48 elements were inactive or showed only
minimal expression (Figure 6a). To validate these data, we
examined an additional K562 RNA-seq dataset to quantify
the MER48-lncRNAs using Cufflinks [36] (Figure 6b).
The highest expressed MER48-lncRNA in this dataset was
EVADR (230 FPKM), consistent with the read count-
derived data in Figure 6a. The lncRNA ENSG00000230257
also showed moderately increased expression (21 FPKM)
in K562 cells, while the expression of the other seven
lncRNAs was low or undetectable (Figure 6b). Collectively,
these results demonstrate that EVADR is specifically acti-
vated and not due to global MER48 activation.
EVADR is a highly conserved, primate-specific lncRNA
Comparative sequence analysis of the EVADR MER48
LTR revealed high (>90%) sequence identity to the
EVADR MER48 LTR in Old World monkeys (OWMs)
and apes. Interestingly, however, the EVADR LTR is ab-
sent in more distant primates, including New World
monkeys (NWMs) and prosimians (Figure 7a,b). The full
394 bp EVADR lncRNA gene demonstrated high se-
quence identity in apes and OWMs, particularly in the
exons, with the introns showing decreasing identity with
increasing phylogenetic distance (Figure 7b; Additional
file 3). Both EVADR introns (i1 and i2) retained con-
served GT/AG splice junctions in the apes and OWMs,
but these junctions were not consistently conserved in
NWMs or prosimians. The high nucleotide conservation
for EVADR corresponds to an evolutionarily conserved
secondary structure in OWMs and apes (Figure 8), with
significantly more variable nucleotide positions occurring
in unpaired or loop positions (47/152) than in structured
regions (39/242 of paired nucleotide positions) (P = 0.0008;
Chi-squared test; Figures S7 and S8 in Additional file 1).
The 39 substitutions in structured regions affected a total
Figure 4 The lncRNA EVADR is partially derived from a MER48 ERV element. (a) Gene structure indicating the MER48 element overlapping
with the 5′ termini of EVADR (red); lncRNA exons are shown in blue, predicted poly(A) signal in yellow and the promoter by a bent arrowhead.
(b) Partial sequences of 10 clones from 5′ RNA ligase-mediated RACE analysis of MER48 initiated EVADR transcripts aligned to human genomic
DNA. The predicted TATA box is indicated by a line, the minor transcriptional start sites by an asterisk, and the predominant initiating nucleotide
is bolded and indicated by a bent arrow. The RNA adaptor sequences are light grey and in lower case. (c) Promoter deletion experimental design
showing truncations of the MER48 element. The MER48 LTR is indicated by a red arrow, the luciferase ORF by green rectangles, and EVADR
is indicated by blue rectangles. (d) Results of the promoter analysis in K562 cells. (e) Results of the promoter analysis in SW480 cells.
*Adjusted P < 0.05; **adjusted P < 0.005; two-sample t-test with Bonferroni correction.
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tutions were compensatory, maintaining base pairing and
20 out of 39 were non-compensatory, disrupting base
pairing (Figure S8 in Additional file 1). Given 4 out of 24random possible nucleotide changes in GC, GU and AU
base pairs would maintain base pairing, we find that nu-
cleotide substitutions in stems are significantly more likely
to be compensatory (19/39 versus 7/39; observed versus
Figure 5 MER48 activation is specific, rather than general, in adenocarcinoma tumors. (a) Clustered heatmap showing the expression of
nine MER48-associated lncRNAs in a panel of colon (COAD; n = 181), rectal (READ; n = 66), pancreatic (PAAD; n = 52), lung (LUAD; n = 372) and
stomach (STAD; n = 136) adenocarcinomas. (b) Expression levels for the same nine MER48-lncRNAs. The y-axis is log2(FPKM + 1) for each set.
Medians are indicated by red lines, upper and lower quartiles by boxes, and outliers by blue crosses.
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Figure 6 MER48 LTRs are not globally active in K562 cells. (a) Scatterplot of expression for 201 reliable MER48 elements in K562, with EVADR
being the highest expressed MER48 element. Plotted values are the average of two experiments. (b) Expression of the nine MER48-lncRNAs in
K562s in a validation dataset. Values are the average of three experiments. The ENSG00000230257 is driven by a MER48 element flanking a
HERVH48 insertion. The ENSG00000261761 lncRNA MER48 is split by an Alu insertion. The lncRNA ENSG00000230258 is associated with an
unreliable MER48 in Dfam [41] and was not, therefore, part of the list used for the scatterplot and does not appear in these data.
Gibb et al. Genome Medicine  (2015) 7:22 Page 11 of 15expected) than non-compensatory (20/39 versus 33/39;
observed versus expected) base pairs in stem regions (P =
7.8e-08, Chi-squared test). These results show the EVADR
lncRNA has strong conservation in primates closest to
humans, at both the primary and secondary structural
levels.
Discussion
We report the tumor-specific activation of EVADR, a
novel lncRNA gene which is associated with a MER48
LTR. This lncRNA demonstrates nominal to low expres-
sion in normal tissue, but is significantly upregulated in
cancer, particularly in colon, rectal, lung, stomach and
pancreas adenocarcinomas.
Approximately 8% of the human genome is composed
of ERV elements [58-60], with a number of ERV1, ERVL-
MaLR, ERVL and ERVK elements overlapping a substan-
tial number of lncRNAs [18]. The MER48 LTR is a
member of the ERV1 class of retroviral elements, andis likely derived from an unknown retrovirus distantly
related to RTVL-H2 [54]. Like other ERV elements, the
MER48 LTRs are prominent in the human genome with
over 200 non-redundant insertions [41], overlapping nine
different lncRNA genes (this study). With at least one
MER48 repeat found inserted into an Alu-J element, the
MER48 repeat can be dated to at most 80 million years
before present [54,61], which is at least 10 million years
after the estimated time of divergence of rodents and pri-
mates [62]. In apes and OWMs, the MER48 LTR and cor-
responding EVADR lncRNA are highly conserved. While
MER48 elements are present in NWMs and prosimians
we could not identify a MER48 insertion at the expected
EVADR locus in these groups (Figure 7). These observa-
tions suggest an active MER48 element inserted at the
EVADR locus sometime after the split between NWMs
and OWMs, but before the split between OWM and apes.
As the MER48 LTR provides a promoter and contributes
sequence to the EVADR exons, it appears the apes and
Figure 7 Sequence conservation of the EVADR lncRNA in primates. (a) Partial sequence alignment of the EVADR MER48 and flanking
sequence in 13 primates showing lack of MER48 LTR in NWMs and prosimians. The major experimentally determined transcriptional start
site (TSS) is indicated by a bent arrow, while the predicted TATA box is indicated by a line. Due to space constraints, some sequence
has been removed and is indicated by NNN and curly brackets. (b) Sequence identity of the EVADR MER48 LTR and EVADR in 13 primate
species determined with SIAS (Methods) on ClustalW aligned sequences. The first and second introns are indicated by an i1 and i2,
respectively. The tree was generated using the UCSC genome tool phlyoGif [45,46]. The black dot indicates a burst of MER48 insertion
as determined by the GEnome-wide Browser for RETroelement (GEBRET) webtool [56]. For GEBRET output and complete sequence alignments
see Figure S9 in Additional file 1 and ClustalW alignments in Additional file 3, respectively.
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lncRNA EVADR and this arrangement has been main-
tained evolutionarily.
Unlike most lncRNAs, which show modest conservation
[5,63-65], the human EVADR lncRNA has remarkably
high sequence identity among non-human primates, simi-
lar to the constrained exonic sequences of protein coding
genes. Analysis of the EVADR consensus structure reveals
the majority of the evolutionary structural base pair sub-
stitutions are compensatory, which strongly suggests the
RNA secondary structure is critical for EVADR function
(Figure 8). Further supporting strong purifying selectionfor EVADR, we find the splice junctions of both introns to
be conserved in apes and OWMs, but not in NWMs or
prosimians. These findings are consistent with previous
reports describing conserved splice junctions for lncRNAs
[66,67]. Many lncRNAs do not have high sequence or
structural conservation and yet can have biological func-
tions [64,68,69]. However, the high level of sequence con-
servation observed for EVADR is atypical; this suggests
the biological function of EVADR may also be manifested
through its RNA structural features rather than its pri-
mary sequence. Collectively, the constraint on the EVADR
exons, splice junctions and promoter sequence, coupled
Figure 8 Human EVADR secondary structure. RNAalifold was
used to predict a secondary structure based on a consensus fold
for apes and OWMs [57]. Shading indicates the 27 base pair
positions with nucleotide substitutions. The EVADR alignments
showing all nucleotide substitutions and a chart showing only
the base pair substitutions are shown in Figures S7 and S8 in
Additional file 1, respectively.
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may play an important, yet undetermined role in primate
biology.
The EVADR MER48 LTR not only contributes se-
quence to the 5′ exon of the lncRNA, but also a functional
promoter that may direct aberrant expression of EVADR
in cancer. We quantified EVADR expression across 25 dif-
ferent TCGA tumor types to find this lncRNA is strongly
associated with colon, rectal, lung, stomach and pancreas
adenocarcinomas, but not with corresponding normal tis-
sues. In general, the eight other MER48-lncRNAs have
low expression in these same tumors and do not correlate
with EVADR tumor expression profiles. Thus, relative
to other MER48-lncRNAs, there is specific activation of
EVADR in these adenocarcinomas. There is a possibility
that EVADR has a non-adenylated form which would notbe detectable in TCGA datasets since they are derived from
poly(A)+ RNA. Two other studies have found ERV LTR-
mediated activation of gene expression in cancer but both
of these studies described protein coding genes that employ
an ERV LTR as an alternative promoter. The first study
reported activation of the colony stimulating factor 1
receptor (CSF1R) gene in Hodgkin’s lymphoma [70] and
the second reported activation of the fatty acid binding
protein 7 (FABP7) gene in diffuse large B-cell lymphoma
[71]. In cancer cell lines there are a number of examples
of the recently described very long intergenic non-coding
RNAs (vlincRNAs) displaying transcriptional activation me-
diated by a ERV [72]. While it is known that ERV LTRs can
drive aberrant expression of protein-coding genes, our study
expands this to show they can modulate the expression of
lncRNAs in human cancer in a highly specific manner.
The adenocarcinoma-specific expression of EVADR sug-
gests this lncRNA may have a distinct function in tissues
and tumors of a glandular origin. Consistent with this
observation, many lncRNAs have been reported to dem-
onstrate tissue- or cell type-specific expression [7,8]. More
recently, another class of ERV-associated lncRNAs,
HERVH-lncRNAs, have been reported to be specific-
ally active in embryonic stem cells, where they are associ-
ated with pluripotency [18,73,74]. However, HERV-H
LTRs also demonstrate stem cell-specific expression [28],
which may suggest the HERVH-lncRNAs are activated, at
least in part, by virtue of their association with the HERV-
LTR. We found no evidence for EVADR expression in
stem cells in our analysis of ENCODE cell line RNA-seq
data (Figure S3B in Additional file 1), but it is possible
EVADR may be active in early developmental processes.
In a manner similar to the HERVH-lncRNAs, the MER48
LTRs may provide a regulatory mechanism to drive tissue-
or tumor-specific lncRNA expression.
Conclusions
The conservation of EVADR in recent primate evolution
and the MER48-mediated activation of EVADR in adeno-
carcinoma highlight the need for further studies to eluci-
date the normal function of EVADR and its relevance
to cancer biology. Ongoing experiments will identify
EVADR’s protein and RNA interacting partners, chromatin
binding sites, and effects on gene expression, and EVADR
knock-in mice will likely be useful for elucidating EVADR’s
biological and oncogenic phenotypes. It is also possible that
the activation of EVADR does not contribute to oncogen-
esis, but rather is a consequence of changes to the tran-
scriptional regulatory environment typical of cancer cells.
Regardless of a biological function, the specificity of EVADR
activation in adenocarcinomas coupled with the poorer sur-
vival probability that tracks with elevated EVADR expres-
sion suggest that further characterization of EVADR as a
candidate adenocarcinoma biomarker is warranted.
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ClustalW alignments for the EVADR cDNA, introns, and MER48 LTR
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